Renalytix secures 10-year US government contract; Medicare coverage decision pending

Renalytix plc

KidneyIntelX.dkd added to 10-year GWAC through GSA, covering VA, DoD, IHS, at $950/result.
NGS holds Open Public Meeting on proposed coverage policy DL39726; final LCD expected FY2024.
Effective Jan 1, 2024, test priced at $950 on CMS CLFS for three years.
These advancements expected to enable insurance coverage for 10M of 14M FDA-indicated patients.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.